A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to anti-TNFalpha Agents

Trial Profile

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to anti-TNFalpha Agents

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms REASSURE 2
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Jul 2018 Primary endpoint (Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20)) has not been met, according to results published in the Scandinavian Journal of Rheumatology.
    • 01 Jul 2018 Results published in the Scandinavian Journal of Rheumatology.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top